Evidence map›Paper›PMID 20730088›Full record

ArticlePLoS pathogens2010

CTCF prevents the epigenetic drift of EBV latency promoter Qp.

Italo Tempera, Andreas Wiedmer, Jayaraju Dheekollu, Paul M Lieberman

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 117 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Chromatin Control of EBV Infection and Latency.Current topics in microbiology and immunology · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Viral remodeling of the 4D nucleome.Experimental & molecular medicine · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Italo TemperaThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Andreas Wiedmer
Jayaraju Dheekollu
Paul M Lieberman
The Wistar Institute · US

Funding

Epigenetic Regulation of Epstein-Barr Virus Latency ProgramsR01DE017336 · NIDCR · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2005 to 2026
$6.5M
Regulation of KSHV LatencyR01CA117830 · NCI · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2006 to 2026
$6.4M
NCI NIH HHS CA117830NCI NIH HHS R01 CA117830NIDCR NIH HHS DE017336NIDCR NIH HHS R01 DE017336
6 · The paper itself

Abstract

The establishment and maintenance of Epstein-Barr Virus (EBV) latent infection requires distinct viral gene expression programs. These gene expression programs, termed latency types, are determined largely by promoter selection, and controlled through the interplay between cell-type specific transcription factors, chromatin structure, and epigenetic modifications. We used a genome-wide chromatin-immunoprecipitation (ChIP) assay to identify epigenetic modifications that correlate with different latency types. We found that the chromatin insulator protein CTCF binds at several key regulatory nodes in the EBV genome and may compartmentalize epigenetic modifications across the viral genome. Highly enriched CTCF binding sites were identified at the promoter regions upstream of Cp, Wp, EBERs, and Qp. Since Qp is essential for long-term maintenance of viral genomes in type I latency and epithelial cell infections, we focused on the role of CTCF in regulating Qp. Purified CTCF bound approximately 40 bp upstream of the EBNA1 binding sites located at +10 bp relative to the transcriptional initiation site at Qp. Mutagenesis of the CTCF binding site in EBV bacmids resulted in a decrease in the recovery of stable hygromycin-resistant episomes in 293 cells. EBV lacking the Qp CTCF site showed a decrease in Qp transcription initiation and a corresponding increase in Cp and Fp promoter utilization at 8 weeks post-transfection. However, by 16 weeks post-transfection, bacmids lacking CTCF sites had no detectable Qp transcription and showed high levels of histone H3 K9 methylation and CpG DNA methylation at the Qp initiation site. These findings provide direct genetic evidence that CTCF functions as a chromatin insulator that prevents the promiscuous transcription of surrounding genes and blocks the epigenetic silencing of an essential promoter, Qp, during EBV latent infection.

Indexed as

Epigenesis, GeneticCCCTC-Binding FactorCell LineChromatinChromatin ImmunoprecipitationChromosome MappingDNA MethylationElectrophoretic Mobility Shift AssayEpstein-Barr Virus InfectionsGene Expression ProfilingGene Expression Regulation, ViralGenes, ViralHerpesvirus 4, HumanHumansPromoter Regions, GeneticRepressor ProteinsCCCTC-Binding FactorChromatinCTCF protein, humanRepressor Proteins

Identifiers

PMID20730088
PMCPMC2921154
OpenAlexW1999331015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.